Fibrocell Science, Inc. Announces Plans For Process Development And Manufacturing Of Genetically-Modified Cell Therapy For Rare Disease, RDEB
5/28/2014 10:03:41 AM
EXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc., (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, announced today that Progenitor Cell Therapy (PCT), a subsidiary of NeoStem, Inc. (NASDAQ:NBS), has been engaged by Fibrocell’s collaborator, Intrexon Corporation (NYSE:XON), to provide production capabilities in the generation of cell therapies for the rare disease Recessive Dystrophic Epidermolysis Bullosa (RDEB). Fibrocell’s clinical program for RDEB will utilize PCT’s manufacturing expertise and resources to implement the production process for transfer and clinical manufacturing of genetically-modified cell therapies. The manufacturing services provided by PCT will augment manufacturing capacity available to Fibrocell through Intrexon, allowing Fibrocell to focus its internal operations on its pipeline of personalized biologic cell therapies.
Help employers find you! Check out all the jobs and post your resume.
comments powered by